Ivantis, Inc. has announced it has raised $46.5 million in series B financing.
Ivantis designs, develops and commercializes technologies to treat glaucoma. It is the developer of the Hydrus microstent device designed to lower eye pressure for glaucoma patients.
Ivantis secured $14 million from Vertex Ventures and GBS Ventures in the final close of the financing round, taking the total up to $46.5 million.
The round included new investors Vertex, GBS, Ascension Ventures, EDBI and MemorialCare Innovation Fund, plus returning investors NEA and Delphi Ventures.
The company announced the funds will support three ongoing clinical trials.